Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 10 Myelodysplastic Syndromes 7 Leukemia, Myelomonocytic, Chronic 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasms 2 Multiple Myeloma 2 Lymphoma 2 Advanced Solid Neoplasm 2 Solid Tumors 1 Renal Insufficiency 1 Neoplasm, Residual 1 Melanoma 1 Liver Diseases 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Central Nervous System Neoplasms 1 Advanced Solid Tumors 1 Advanced Nonhematologic Malignancies 1

Interventions

Ipilimumab 114 pembrolizumab 95 Nivolumab 91 aldesleukin 86 Interleukin-2 57 Cyclophosphamide 54 Dacarbazine 52 Vemurafenib 39 trametinib 37 Temozolomide 37 incomplete Freund's adjuvant 35 fludarabine phosphate 35 sargramostim 32 dabrafenib 32 fludarabine 26 Bevacizumab 26 Paclitaxel 22 MART-1 Antigen 21 Granulocyte-Macrophage Colony-Stimulating Factor 21 montanide ISA 51 20 Interferon-alpha 20 Cisplatin 20 Carboplatin 19 Sorafenib 18 Introns 17 Biopsy 17 cobimetinib 16 Radiosurgery 16 atezolizumab 15 Radiotherapy 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Melanoma × pevonedistat × Clear all

NCT01011530 2013-07-16

Dose Escalation Study of MLN4924 in Adults With Melanoma

Millennium Pharmaceuticals, Inc.

Phase 1 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡